Literature DB >> 17093192

GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.

Zihong Chen1, Yann Benureau, Rene Rijnbrand, Jianzhong Yi, Ting Wang, Lucile Warter, Robert E Lanford, Steven A Weinman, Stanley M Lemon, Annette Martin, Kui Li.   

Abstract

Understanding the mechanisms of hepatitis C virus (HCV) pathogenesis and persistence has been hampered by the lack of small, convenient animal models. GB virus B (GBV-B) is phylogenetically the closest related virus to HCV. It causes generally acute and occasionally chronic hepatitis in small primates and is used as a surrogate model for HCV. It is not known, however, whether GBV-B has evolved strategies to circumvent host innate defenses similar to those of HCV, a property that may contribute to HCV persistence in vivo. We show here in cultured tamarin hepatocytes that GBV-B NS3/4A protease, but not a related catalytically inactive mutant, effectively blocks innate intracellular antiviral responses signaled through the RNA helicase, retinoic acid-inducible gene I (RIG-I), an essential sensor molecule that initiates host defenses against many RNA viruses, including HCV. GBV-B NS3/4A protease specifically cleaves mitochondrial antiviral signaling protein (MAVS; also known as IPS-1/Cardif/VISA) and dislodges it from mitochondria, thereby disrupting its function as a RIG-I adaptor and blocking downstream activation of both interferon regulatory factor 3 and nuclear factor kappa B. MAVS cleavage and abrogation of virus-induced interferon responses were also observed in Huh7 cells supporting autonomous replication of subgenomic GBV-B RNAs. Our data indicate that, as in the case of HCV, GBV-B has evolved to utilize its major protease to disrupt RIG-I signaling and impede innate antiviral defenses. These data provide further support for the use of GBV-B infection in small primates as an accurate surrogate model for deciphering virus-host interactions in hepacivirus pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093192      PMCID: PMC1797450          DOI: 10.1128/JVI.02076-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Triggering the interferon antiviral response through an IKK-related pathway.

Authors:  Sonia Sharma; Benjamin R tenOever; Nathalie Grandvaux; Guo-Ping Zhou; Rongtuan Lin; John Hiscott
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

2.  Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.

Authors:  Masahiro Yamamoto; Shintaro Sato; Kiyotoshi Mori; Katsuaki Hoshino; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

3.  Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees.

Authors:  J Bukh; C L Apgar; S Govindarajan; R H Purcell
Journal:  J Med Virol       Date:  2001-12       Impact factor: 2.327

4.  Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.

Authors:  Eileen Foy; Kui Li; Chunfu Wang; Rhea Sumpter; Masanori Ikeda; Stanley M Lemon; Michael Gale
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

5.  Processing of GB virus B non-structural proteins in cultured cells requires both NS3 protease and NS4A cofactor.

Authors:  Andrea Sbardellati; Elisa Scarselli; Viviana Amati; Sabrina Falcinelli; Alexander S Kekulé; Cinzia Traboni
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

6.  Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes.

Authors:  Nathalie Grandvaux; Marc J Servant; Benjamin tenOever; Ganes C Sen; Siddarth Balachandran; Glen N Barber; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.

Authors:  Hiroyuki Oshiumi; Misako Matsumoto; Kenji Funami; Takashi Akazawa; Tsukasa Seya
Journal:  Nat Immunol       Date:  2003-01-21       Impact factor: 25.606

Review 8.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

9.  Cell clones selected from the Huh7 human hepatoma cell line support efficient replication of a subgenomic GB virus B replicon.

Authors:  Amedeo De Tomassi; Maura Pizzuti; Rita Graziani; Andrea Sbardellati; Sergio Altamura; Giacomo Paonessa; Cinzia Traboni
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

View more
  80 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Emerging principles governing signal transduction by pattern-recognition receptors.

Authors:  Jonathan C Kagan; Gregory M Barton
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-11-13       Impact factor: 10.005

3.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.

Authors:  Keith P Romano; Akbar Ali; William E Royer; Celia A Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

Review 4.  Emerging Roles of Protein Deamidation in Innate Immune Signaling.

Authors:  Jun Zhao; Junhua Li; Simin Xu; Pinghui Feng
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury.

Authors:  Ling-Juan Zhang; George L Sen; Nicole L Ward; Andrew Johnston; Kimberly Chun; Yifang Chen; Christopher Adase; James A Sanford; Nina Gao; Melanie Chensee; Emi Sato; Yi Fritz; Jaymie Baliwag; Michael R Williams; Tissa Hata; Richard L Gallo
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

6.  The Andes Orthohantavirus NSs Protein Antagonizes the Type I Interferon Response by Inhibiting MAVS Signaling.

Authors:  Jorge Vera-Otarola; Loretto Solis; Fernando Lowy; Valeria Olguín; Jenniffer Angulo; Karla Pino; Nicole D Tischler; Carola Otth; Paula Padula; Marcelo López-Lastra
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 7.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  MAVS-dependent host species range and pathogenicity of human hepatitis A virus.

Authors:  Asuka Hirai-Yuki; Lucinda Hensley; David R McGivern; Olga González-López; Anshuman Das; Hui Feng; Lu Sun; Justin E Wilson; Fengyu Hu; Zongdi Feng; William Lovell; Ichiro Misumi; Jenny P-Y Ting; Stephanie Montgomery; John Cullen; Jason K Whitmire; Stanley M Lemon
Journal:  Science       Date:  2016-09-15       Impact factor: 47.728

9.  Inhibition of sphingosine kinase by bovine viral diarrhea virus NS3 is crucial for efficient viral replication and cytopathogenesis.

Authors:  Daisuke Yamane; Muhammad A Zahoor; Yassir M Mohamed; Walid Azab; Kentaro Kato; Yukinobu Tohya; Hiroomi Akashi
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

10.  Modulation of GB virus B RNA abundance by microRNA-122: dependence on and escape from microRNA-122 restriction.

Authors:  Selena M Sagan; Peter Sarnow; Joyce A Wilson
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.